Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 8/21/2024 | $10.00 | Buy | Lake Street |
| 9/12/2023 | $10.00 → $4.50 | Neutral → Underperform | BofA Securities |
| 9/12/2023 | $15.00 → $5.50 | Overweight → Neutral | Piper Sandler |
| 9/12/2023 | Outperform → Mkt Perform | William Blair | |
| 8/24/2023 | $12.00 → $8.40 | Overweight → Equal-Weight | Morgan Stanley |
| 7/10/2023 | $15.00 → $9.00 | Buy → Neutral | Citigroup |
| 1/6/2023 | $10.00 → $15.00 | Hold → Buy | Stifel |
| 10/4/2022 | Hold | Needham |
MENLO PARK, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will report financial results for the third quarter ended September 30, 2024, after the market close on Thursday, November 7, 2024. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.sightsci
MENLO PARK, Calif., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today reported financial results for the second quarter ended June 30, 2024, and narrowed financial guidance for full year 2024. Recent Business and Second Quarter 2024 Financial Highlights Generated total revenue of $21.4 million, an increase of 11% compared to the prior quarter and a decrease of 9% compared to the same period in the prior year.Achieved total gross margin of 86%
MENLO PARK, Calif., July 18, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will report financial results for the second quarter ended June 30, 2024, after the market close on Thursday, August 1, 2024. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.sightsciences.
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
MENLO PARK, Calif., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced it will report financial results for the third quarter ended September 30, 2024, after the market close on Thursday, November 7, 2024. The Company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. Investors interested in listening to the conference call may do so by accessing a live and archived webcast of the event at www.sightsci
MENLO PARK, Calif., Oct. 14, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, announced today that a new study titled, Impact of TearCare on Reading Speed in Patients with Dry Eye Disease, has been published in the peer-reviewed journal Clinical Ophthalmology. Key study findings reported in the study manuscript include: 52% of participants (N = 32) had a clinically significant improvement in reading speed after therapy with TearCare, defined as a greater than 10 words per minute increase in the
MENLO PARK, Calif., Aug. 20, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies that elevate the standard of care, today announced that it will present at the upcoming Morgan Stanley Global Healthcare Conference, in New York, NY. Sight Sciences' management is scheduled to present on Wednesday, September 4, 2024, at 1:50 pm PT / 4:50 pm ET. Interested parties may access a live and archived webcast of the fireside chat on the "Investors" section of the company's website at: investors.sightsciences.com. About Sight SciencesSight Scienc
Morgan Stanley analyst Cecilia Furlong maintains Sight Sciences (NASDAQ:SGHT) with a Equal-Weight and raises the price target from $5.4 to $6.5.
Citigroup analyst Joanne Wuensch maintains Sight Sciences (NASDAQ:SGHT) with a Neutral and raises the price target from $6 to $6.5.
Lake Street initiated coverage of Sight Sciences with a rating of Buy and set a new price target of $10.00
BofA Securities downgraded Sight Sciences from Neutral to Underperform and set a new price target of $4.50 from $10.00 previously
Piper Sandler downgraded Sight Sciences from Overweight to Neutral and set a new price target of $5.50 from $15.00 previously
MENLO PARK, Calif., Sept. 11, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences," or the "Company"), an eyecare technology company focused on developing and commercializing innovative technology intended to transform care and improve patients' lives, today announced the appointment of Matthew Link as its Chief Commercial Officer, effective September 11, 2023. "We are very excited to have Matt join Sight Sciences as we scale our Surgical Glaucoma and Dry Eye businesses. Matt is a highly talented medtech business leader with a track record of success in transforming treatment paradigms with disruptive new technology, and predictably scaling in a public high-growth
MENLO PARK, Calif., April 03, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announces the appointment of Alison "Ali" Bauerlein as its Chief Financial Officer and Treasurer, effective April 3, 2023. "I am incredibly excited to have Ali join Sight Sciences as we scale our business and drive towards profitable growth. Ali is an exceptionally talented professional with a proven track record of leading a rapidly growing medtech organization through multiple phases of growth. Her experience and talent will prov
MENLO PARK, Calif., Jan. 09, 2023 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (NASDAQ:SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on creating innovative solutions intended to transform care and improve patients' lives, today announces several Company updates. Preliminary Revenue ResultsThe Company is announcing preliminary unaudited financial results for the fourth quarter and year ended December 31, 2022. Fourth quarter 2022 total revenue is expected to be in the range of $20.4 million to $20.6 million, an increase of 40% compared to the prior year period and a sequential increase of 10% compared to the third quarter of 2022 at the estimated midpoint.
8-K - Sight Sciences, Inc. (0001531177) (Filer)
8-K - Sight Sciences, Inc. (0001531177) (Filer)
10-Q - Sight Sciences, Inc. (0001531177) (Filer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
4 - Sight Sciences, Inc. (0001531177) (Issuer)
SC 13G/A - Sight Sciences, Inc. (0001531177) (Subject)
SC 13G - Sight Sciences, Inc. (0001531177) (Subject)
SC 13G/A - Sight Sciences, Inc. (0001531177) (Subject)